tiprankstipranks
Atossa Therapeutics (MX:ATOS)
:ATOS
Mexico Market
ATOS
Atossa Therapeutics
RESEARCH TOOLSreports

Atossa Therapeutics (ATOS) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

ATOS Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Atossa
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ATOS Stock 12 Month Forecast

Average Price Target

$278.12
▲(562.34% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Atossa Therapeutics in the last 3 months. The average price target is $278.12 with a high forecast of $347.64 and a low forecast of $208.59. The average price target represents a 562.34% change from the last price of $41.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","348":"$348","111.75":"$111.8","190.5":"$190.5","269.25":"$269.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":347.6447072,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$347.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":278.11576576000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$278.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":208.58682432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$208.59</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,111.75,190.5,269.25,348],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.8,58.86497747692307,82.92995495384616,106.99493243076924,131.05990990769232,155.1248873846154,179.18986486153847,203.25484233846157,227.31981981538462,251.38479729230772,275.44977476923077,299.5147522461539,323.579729723077,{"y":347.6447072,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.8,53.516597366153846,72.2331947323077,90.94979209846154,109.66638946461539,128.38298683076925,147.0995841969231,165.81618156307695,184.5327789292308,203.24937629538465,221.9659736615385,240.68257102769235,259.3991683938462,{"y":278.11576576000004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.8,48.16821725538461,61.536434510769226,74.90465176615385,88.27286902153845,101.64108627692308,115.00930353230768,128.37752078769228,141.74573804307693,155.11395529846152,168.48217255384617,181.85038980923076,195.21860706461536,{"y":208.58682432,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":258,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.849,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 87, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.8,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 72, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$347.64Average Price Target$278.12Lowest Price Target$208.59
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Rodman & Renshaw Analyst forecast on MX:ATOS
Michael King
Rodman & Renshaw
Rodman & Renshaw
$209.81
Buy
399.67%
Upside
Initiated
07/07/26
Atossa Therapeutics initiated with a Buy at Rodman & RenshawAtossa Therapeutics initiated with a Buy at Rodman & Renshaw
Maxim Group Analyst forecast on MX:ATOS
Jason McCarthy
Maxim Group
Maxim Group
$349.69
Buy
732.79%
Upside
Reiterated
06/02/26
Atossa: Buy Rating Reiterated as DMD and Oncology Pipeline Advances; $20 Price Target Unchanged
Ascendiant Analyst forecast on MX:ATOS
Edward Woo
Ascendiant
Ascendiant
$419.62
Buy
899.34%
Upside
Reiterated
04/09/26
Craig-Hallum Analyst forecast on MX:ATOS
Albert Lowe
Craig-Hallum
Craig-Hallum
$611.95→$174.84
Buy
316.39%
Upside
Reiterated
02/12/26
Analysts Are Bullish on These Healthcare Stocks: QuidelOrtho (QDEL), Atossa Therapeutics (ATOS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Rodman & Renshaw Analyst forecast on MX:ATOS
Michael King
Rodman & Renshaw
Rodman & Renshaw
$209.81
Buy
399.67%
Upside
Initiated
07/07/26
Atossa Therapeutics initiated with a Buy at Rodman & RenshawAtossa Therapeutics initiated with a Buy at Rodman & Renshaw
Maxim Group Analyst forecast on MX:ATOS
Jason McCarthy
Maxim Group
Maxim Group
$349.69
Buy
732.79%
Upside
Reiterated
06/02/26
Atossa: Buy Rating Reiterated as DMD and Oncology Pipeline Advances; $20 Price Target Unchanged
Ascendiant Analyst forecast on MX:ATOS
Edward Woo
Ascendiant
Ascendiant
$419.62
Buy
899.34%
Upside
Reiterated
04/09/26
Craig-Hallum Analyst forecast on MX:ATOS
Albert Lowe
Craig-Hallum
Craig-Hallum
$611.95→$174.84
Buy
316.39%
Upside
Reiterated
02/12/26
Analysts Are Bullish on These Healthcare Stocks: QuidelOrtho (QDEL), Atossa Therapeutics (ATOS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Atossa Therapeutics

3 Months
Edward WooAscendiant
Success Rate
3/13 ratings generated profit
23%
Average Return
-12.75%
reiterated a buy rating 4 months ago
Copying Edward Woo's trades and holding each position for 3 Months would result in 23.08% of your transactions generating a profit, with an average return of -12.75% per trade.
1 Year
Edward WooAscendiant
Success Rate
2/13 ratings generated profit
15%
Average Return
-20.27%
reiterated a buy rating 4 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -20.27% per trade.
2 Years
Edward WooAscendiant
Success Rate
4/13 ratings generated profit
31%
Average Return
-45.59%
reiterated a buy rating 4 months ago
Copying Edward Woo's trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -45.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATOS Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
5
6
7
6
5
Buy
1
1
0
0
0
Hold
24
42
50
87
72
Sell
0
0
0
6
9
Strong Sell
0
0
0
0
0
total
30
49
57
99
86
In the current month, ATOS has received 5 Buy Ratings, 72 Hold Ratings, and 9 Sell Ratings. ATOS average Analyst price target in the past 3 months is 278.12.
Each month's total comprises the sum of three months' worth of ratings.

ATOS Financial Forecast

ATOS Earnings Forecast

Next quarter’s earnings estimate for ATOS is -$17.88 with a range of -$18.66 to -$17.09. The previous quarter’s EPS was -$19.36. ATOS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year ATOS has Performed in-line its overall industry.
Next quarter’s earnings estimate for ATOS is -$17.88 with a range of -$18.66 to -$17.09. The previous quarter’s EPS was -$19.36. ATOS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year ATOS has Performed in-line its overall industry.
No data currently available

ATOS Sales Forecast

Next quarter’s sales forecast for ATOS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ATOS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year ATOS has Performed in-line its overall industry.
Next quarter’s sales forecast for ATOS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ATOS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year ATOS has Performed in-line its overall industry.

ATOS Stock Forecast FAQ

What is MX:ATOS’s average 12-month price target, according to analysts?
Based on analyst ratings, Atossa Therapeutics’s 12-month average price target is 278.12.
    What is MX:ATOS’s upside potential, based on the analysts’ average price target?
    Atossa Therapeutics has 562.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Atossa Therapeutics a Buy, Sell or Hold?
          Atossa Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Atossa Therapeutics’s share price target?
            The average share price target for Atossa Therapeutics is 278.12. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $347.64 ,and the lowest forecast is $208.59. The average share price target represents 562.34% Increase from the current price of $41.99.
              What do analysts say about Atossa Therapeutics?
              Atossa Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Atossa Therapeutics?
                To buy shares of MX:ATOS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.